Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027
Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027
Pfizer Inc. (NYSE:PFE) has launched a multi-year cost-cutting initiative aimed at saving approximately $1.5 billion by the end of 2027.
輝瑞公司（紐約證券交易所代碼：PFE）啓動了一項爲期多年的削減成本的計劃，旨在到2027年底節省約15億美元。
What Happened: The new program builds on a $4 billion cost reduction plan announced last year, Reuters reported on Thursday. This move comes as the company faces declining investor interest and diminishing sales from its COVID-19 vaccine and treatments.
發生了什麼：路透社週四報道，新計劃建立在去年宣佈的40億美元成本削減計劃的基礎上。此舉是在該公司面臨投資者興趣下降以及其 COVID-19 疫苗和治療的銷售減少之際採取的。
Pfizer's shares rose 2.6% to $29.30 in afternoon trading but remain down about 24% over the past year and nearly half of their peak value from December 2021. The company disclosed the new program in a filing with the Securities and Exchange Commission.
輝瑞的股價在下午的交易中上漲了2.6％，至29.30美元，但在過去一年中仍下跌了約24％，是自2021年12月以來峯值的近一半。該公司在向美國證券交易委員會提交的文件中披露了新計劃。
The program will incur one-time charges of $1.7 billion, mainly for severance and implementation costs, with most charges expected this year. Actual cash outlays are anticipated in 2025 and 2026.
該計劃將產生17億美元的一次性費用，主要用於遣散費和實施費用，預計今年將收取大部分費用。實際現金支出預計將在2025年和2026年出現。
Pfizer aims to enhance operational efficiencies, restructure its network, and improve its product portfolio. No job cuts have been announced yet, but further details will be shared in future earnings calls and investor events.
輝瑞旨在提高運營效率，重組其網絡並改善其產品組合。尚未宣佈裁員，但將在未來的業績電話會議和投資者活動中分享更多細節。
Earlier this month, Pfizer raised its annual earnings forecast and reported a better-than-expected first-quarter profit, partly due to cost reductions. Chief Financial Officer David Denton highlighted the strong cost control across their manufacturing platform.
本月早些時候，輝瑞上調了年度收益預期，並公佈了好於預期的第一季度利潤，部分原因是成本降低。首席財務官戴維·丹頓強調了整個製造平台的強大成本控制。
Why It Matters: Pfizer's cost-cutting measures come at a crucial time for the pharmaceutical giant. Earlier this year, the company surprised analysts with a profit, largely driven by its efforts to revolutionize cancer treatment. Pfizer's focus on innovative cancer therapies could be its best chance to regain investor confidence.
爲何重要：輝瑞的削減成本措施是在這家制藥巨頭的關鍵時刻出臺的。今年早些時候，該公司的盈利令分析師感到驚訝，這主要是由其徹底改變癌症治療的努力所推動的。輝瑞對創新癌症療法的關注可能是其恢復投資者信心的最佳機會。
However, Pfizer has been grappling with reduced revenue from its COVID-19 treatments. The company acknowledged the financial headwinds it faces due to declining sales of its COVID-19 products. This has put additional pressure on Pfizer to find new revenue streams and cut costs effectively.
但是，輝瑞一直在努力解決其 COVID-19 治療收入減少的問題。該公司承認由於其 COVID-19 產品銷售下降而面臨財務阻力。這給輝瑞帶來了額外的壓力，要求他們尋找新的收入來源並有效削減成本。
Price Action: On Thursday, Pfizer closed 3.64% higher at $29.60 while it was trading 0.17% lower at $29.55 on Friday's pre-market, according to Benzinga Pro.
價格走勢：根據Benzinga Pro的數據，輝瑞週四收盤上漲3.64％，至29.60美元，而週五盤前交易價格下跌0.17％，至29.55美元。
Photo via Shutterstock
照片來自 Shutterstock
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
這個故事是使用 Benzinga Neuro 創作的，由 Pooja Rajkumari
譯文內容由第三人軟體翻譯。